ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.04M | -26.03M | -23.33M | -29.13M | -30.40M |
| Total Depreciation and Amortization | 2.99M | 3.06M | 3.00M | 2.88M | 2.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.04M | -857.50K | -2.04M | -1.67M | -1.94M |
| Change in Net Operating Assets | -14.33M | -11.28M | -14.69M | -13.67M | 52.42M |
| Cash from Operations | -39.34M | -35.11M | -37.06M | -41.59M | 22.80M |
| Capital Expenditure | -1.54M | -2.04M | -2.10M | -2.13M | -1.48M |
| Sale of Property, Plant, and Equipment | -- | 14.00K | 14.00K | 14.00K | 64.40K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.60M | 6.25M | -12.44M | -12.44M | 6.02M |
| Cash from Investing | -4.13M | 4.22M | -14.52M | -14.56M | 4.60M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.58M | -2.62M | -2.60M | -2.95M | -2.63M |
| Issuance of Common Stock | 71.86M | 374.00K | 524.00K | 516.00K | 354.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 74.89M | -2.43M | -2.24M | -2.64M | -2.46M |
| Foreign Exchange rate Adjustments | 713.60K | -275.70K | 42.90K | 912.30K | 657.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.12M | -33.60M | -53.78M | -57.87M | 25.60M |